Mesoblast Limited (MEOBF)
| Previous Close | 0.8589 |
| Open | 0.8589 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.8589 - 0.8589 |
| 52 Week Range | 0.8000 - 1.7400 |
| Volume | |
| Avg. Volume | 10,321 |
| Market Cap | 556.019M |
| Beta (5Y Monthly) | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1560 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry?
The big shareholder groups in Mesoblast Limited ( ASX:MSB ) have power over the company. Institutions will often hold...
- GlobeNewswire
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with US$25.8 million in the comparativ
- Zacks
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
